Coverage for Rituximab

On May 12, 2022, Gov. Hogan signed HB 820 into law. The new law requires health insurance policies issued or renewed on or after January 1, 2023, to provide coverage for rituximab for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute onset neuropsychiatric syndrome (PANS).

Employer plan sponsors of fully insured policies issued in Maryland should be aware of the coverage change and work with the insurer to update plan documents as necessary.

HB 820 »